In the aftermath of several deals with smaller biotechs made in the 13 months in the cardiometabolic space, Novo Nordisk has ...

Partnership combines AbTherx's proprietary Atlas™ Long CDR3 Technology with GPCR Therapeutics' deep expertise in GPCR biology to discover and develop antibodies for novel targets MOUNTAIN VIEW, CA / ...

AbCellera Biologics' drug candidates in Phase 1 trials show promise, but financial losses and slow progress raise concerns.

Williams, W. R. (2025) Nucleotide Relative Molecular Similarity within Anti-Psychotic Drug Structures. Journal of Biosciences and Medicines, 13, 106-117. doi: 10.4236/jbm.2025.136010 .

Deep Apple collaborates with Novo Nordisk to discover and develop oral therapeutics for cardiometabolic diseases: South San Francisco, California Thursday, June 12, 2025, 18:00 Hr ...

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

Salipro Biotech & Daewoong Pharmaceutical collaborate to advance development of novel therapeutics: Seoul, Korea Thursday, June 12, 2025, 16:00 Hrs [IST] Swedish biotech company S ...

Deep Apple Therapeutics, Inc. has announced a research collaboration and exclusive worldwide license agreement with Novo ...

Danish pharma major Novo Nordisk and privately-held Californian firm Deep Apple Therapeutics have announced a research ...

Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an unspecified up-front payment, research costs ...

Novo Nordisk and Deep Apple Therapeutics Inc. have entered a research collaboration and exclusive license agreement.